Response rates in acute myeloid leukemia patients treated with attenuated durations of venetoclax in combination with hypomethylating agents.

Dena Blanding,Bakos Keegan Jonathan,Christopher Andrew Rangel,Sarah Pasyar,Elizabeth G. Hill,James Davis,Brian T. Hess,Praneeth Baratam,Irl Brian Greenwell

Response rates in acute myeloid leukemia patients treated with attenuated durations of venetoclax in combination with hypomethylating agents.

2021

Dena Blanding
Bakos Keegan Jonathan
Christopher Andrew Rangel
Sarah Pasyar
Elizabeth G. Hill
James Davis
Brian T. Hess
Praneeth Baratam
Irl Brian Greenwell

e19008Background: The combination of the Bcl-2 inhibitor, venetoclax, with hypomethylating agents (HMA) recently emerged as an efficacious treatment for older adults with acute myeloid leukemia (AM...

Keywords:

Medicine
Oncology
Internal medicine
Myeloid leukemia
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations